Clinical Trials Logo

Inflammatory Lung Diseases clinical trials

View clinical trials related to Inflammatory Lung Diseases.

Filter by:
  • Completed  
  • Page 1

NCT ID: NCT01171768 Completed - Hemoptysis Clinical Trials

The Expression of Serum Angiogenesis Marker in Patients Presenting With Hemoptysis

Start date: June 2008
Phase: N/A
Study type: Observational

Vascular endothelial growth factor (VEGF) and angiopoietin-2 (Ang-2) are major mediators of angiogenesis and are induced by tissue inflammation and hypoxia. While elevated serum VEGF levels have been reported in inflammatory lung diseases, especially with hemoptysis, there was no study to evaluate the Ang-2 levels in lung inflammatory diseases according to the presence of hemoptysis, inflammatory biomarker and hypoxia.